《大行》摩通首予科伦博泰生物(06990.HK)“增持”评级 目标价240元

阿斯达克财经
Dec 17, 2024

摩根大通发表研究报告指,首予科伦博泰生物-B(06990.HK) “增持”评级,目标价240元。科伦博泰生物成立于2016年,目前,其在中国市场拥有一款抗体药物偶联物(ADC) SKB264,并且有八个ADC正在进行临床测试中,另有三个非ADC癌症药物正在中国的新药申请(NDA)审批之中。摩通续提到,默沙东(MRK.US)  拥有SKB264在大中华区以外的开发、使用、制造及商业化权利,并启动了...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10